Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12967-020-02218-x.

Title:
Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy | Journal of Translational Medicine
Description:
Background We have previously shown that HCC patients and healthy subjects are equally responsive to a RNAdjuvantĀ®, a novel TLR-7/8/RIG-I agonist based on noncoding RNA developed by CureVac, by an ex vivo evaluation. However, the immunological effect of adjuvants on immune cells from cancer patients undergoing chemotherapy remains to be demonstrated. Different adjuvants currently used in cancer vaccine clinical trials were evaluated in the present study on immune cells from cancer patients before and after chemotherapy in an ex vivo setting. Methods PBMCs were obtained from 4 healthy volunteers and 23 patients affected by either colon (OMA) or lung cancer (OT). The effect of CpG, Poly I:C, Imiquimod and RNA-based adjuvant (RNAdjuvantĀ®) was assessed using a multiparametric approach to analyze network dynamics of early immune responses. Evaluation of CD80, CD86 and HLA-DR expression as well as the downstream effect on CD4+ T cell phenotyping was performed by flow cytometry; cytokine and chemokine production was evaluated by Bio-Plex ProTM. Results Treatment with RNAdjuvantĀ® induced the strongest response in cancer patients in terms of activation of innate and adoptive immunity. Indeed, CD80, CD86 and HLA-DR expression was found upregulated in circulating dendritic cells, which promoted a CD4+ T cell differentiation towards an effector phenotype. RNAdjuvantĀ® was the only one to induce most of the cytokines/chemokines tested with a pronounced Th1 cytokine pattern. According to the different parameters evaluated in the study, no clear cut difference in immune response to adjuvants was observed between healthy subjects and cancer patients. Moreover, in the latter group, the chemotherapy treatment did not consistently correlate to a significant altered response in the different parameters. Conclusions The present study is the first analysis of immunological effects induced by adjuvants in cancer patients who undergo chemotherapy, who are enrolled in the currently ongoing cancer vaccine clinical trials. The results show that the RNAdjuvantĀ® is a potent and Th1 driving adjuvant, compared to those tested in the present study. Most importantly, it is demonstrated that chemotherapy does not significantly impair the immune system, implying that cancer patients are likely to respond to a cancer vaccine even after a chemotherapy treatment.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {šŸ“š}

  • Health & Fitness
  • Science
  • Education

Content Management System {šŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {šŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {šŸ’ø}

We're unsure how the site profits.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {šŸ”}

patients, cancer, adjuvants, cells, pubmed, samples, expression, article, subjects, markers, induced, google, scholar, healthy, rnadjuvant, chemotherapy, compared, cas, pre, postchemotherapy, results, treatment, immune, vivo, vaccine, evaluated, fig, lung, cell, central, pbmcs, colon, significant, flow, analyzed, ccl, adjuvant, cytometry, percentage, showed, hladr, circulating, positive, induce, control, negative, monocytes, buonaguro, effector, vaccines,

Topics {āœ’ļø}

maria lina tornesello favorable safety profile view immunomodulatory profile beatrice cavalluzzo author information authors bio-plex manager software hcv-related lymphoproliferative disorders original author article download pdf anti-infective vaccination strategies vivo t-cell responses luigi buonaguro long-lasting immune response rationale-based combined treatments bio-plex protm author human immunodeficiency virus elicit antigen-specific ctl rna-based adjuvant liver cancer patients immune-inhibitory il-10 cytokine post-chemotherapy blood samples boost antigen-specific humoral medium-term culture anti-tumor agent cancer immunotherapy maria tagliamonte short-term culture adaptive immune response cellular immune response central role played post-chemotherapy cancer patients privacy choices/manage cookies polyinosinic–polycytidylic acid early immune responses cancer vaccine development translational medicine aims van der velden transcan2—hepamut project influenza virus vaccination bio-plex th1-type response full access circulating antigen-presenting cells innate immune response therapeutic cancer vaccines monoclonal antibodies specific clin cancer res anti-cancer immunity

Schema {šŸ—ŗļø}

WebPage:
      mainEntity:
         headline:Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy
         description:We have previously shown that HCC patients and healthy subjects are equally responsive to a RNAdjuvantĀ®, a novel TLR-7/8/RIG-I agonist based on noncoding RNA developed by CureVac, by an ex vivo evaluation. However, the immunological effect of adjuvants on immune cells from cancer patients undergoing chemotherapy remains to be demonstrated. Different adjuvants currently used in cancer vaccine clinical trials were evaluated in the present study on immune cells from cancer patients before and after chemotherapy in an ex vivo setting. PBMCs were obtained from 4 healthy volunteers and 23 patients affected by either colon (OMA) or lung cancer (OT). The effect of CpG, PolyĀ I:C, Imiquimod and RNA-based adjuvant (RNAdjuvantĀ®) was assessed using a multiparametric approach to analyze network dynamics of early immune responses. Evaluation of CD80, CD86 and HLA-DR expression as well as the downstream effect on CD4+ T cell phenotyping was performed by flow cytometry; cytokine and chemokine production was evaluated by Bio-Plex ProTM. Treatment with RNAdjuvantĀ® induced the strongest response in cancer patients in terms of activation of innate and adoptive immunity. Indeed, CD80, CD86 and HLA-DR expression was found upregulated in circulating dendritic cells, which promoted a CD4+ T cell differentiation towards an effector phenotype. RNAdjuvantĀ® was the only one to induce most of the cytokines/chemokines tested with a pronounced Th1 cytokine pattern. According to the different parameters evaluated in the study, no clear cut difference in immune response to adjuvants was observed between healthy subjects and cancer patients. Moreover, in the latter group, the chemotherapy treatment did not consistently correlate to a significant altered response in the different parameters. The present study is the first analysis of immunological effects induced by adjuvants in cancer patients who undergo chemotherapy, who are enrolled in the currently ongoing cancer vaccine clinical trials. The results show that the RNAdjuvantĀ® is a potent and Th1 driving adjuvant, compared to those tested in the present study. Most importantly, it is demonstrated that chemotherapy does not significantly impair the immune system, implying that cancer patients are likely to respond to a cancer vaccine even after a chemotherapy treatment.
         datePublished:2020-01-23T00:00:00Z
         dateModified:2020-01-23T00:00:00Z
         pageStart:1
         pageEnd:17
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12967-020-02218-x
         keywords:
            Adjuvant
            Colon cancer
            Lung cancer
            Immune-response
            Cancer vaccine
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig8_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig9_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig10_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig11_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig12_HTML.png
         isPartOf:
            name:Journal of Translational Medicine
            issn:
               1479-5876
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Angela Mauriello
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Carmen Manolio
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Beatrice Cavalluzzo
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Antonio Avallone
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:GI Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marco Borrelli
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alessandro Morabito
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Emanuele Iovine
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Angela Chambery
               affiliation:
                     name:UniversitĆ  della Campania ā€œLuigi Vanvitelliā€
                     address:
                        name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rosita Russo
               affiliation:
                     name:UniversitĆ  della Campania ā€œLuigi Vanvitelliā€
                     address:
                        name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maria Lina Tornesello
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Franco M. Buonaguro
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maria Tagliamonte
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Luigi Buonaguro
               url:http://orcid.org/0000-0002-6380-7114
               affiliation:
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                     address:
                        name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy
      description:We have previously shown that HCC patients and healthy subjects are equally responsive to a RNAdjuvantĀ®, a novel TLR-7/8/RIG-I agonist based on noncoding RNA developed by CureVac, by an ex vivo evaluation. However, the immunological effect of adjuvants on immune cells from cancer patients undergoing chemotherapy remains to be demonstrated. Different adjuvants currently used in cancer vaccine clinical trials were evaluated in the present study on immune cells from cancer patients before and after chemotherapy in an ex vivo setting. PBMCs were obtained from 4 healthy volunteers and 23 patients affected by either colon (OMA) or lung cancer (OT). The effect of CpG, PolyĀ I:C, Imiquimod and RNA-based adjuvant (RNAdjuvantĀ®) was assessed using a multiparametric approach to analyze network dynamics of early immune responses. Evaluation of CD80, CD86 and HLA-DR expression as well as the downstream effect on CD4+ T cell phenotyping was performed by flow cytometry; cytokine and chemokine production was evaluated by Bio-Plex ProTM. Treatment with RNAdjuvantĀ® induced the strongest response in cancer patients in terms of activation of innate and adoptive immunity. Indeed, CD80, CD86 and HLA-DR expression was found upregulated in circulating dendritic cells, which promoted a CD4+ T cell differentiation towards an effector phenotype. RNAdjuvantĀ® was the only one to induce most of the cytokines/chemokines tested with a pronounced Th1 cytokine pattern. According to the different parameters evaluated in the study, no clear cut difference in immune response to adjuvants was observed between healthy subjects and cancer patients. Moreover, in the latter group, the chemotherapy treatment did not consistently correlate to a significant altered response in the different parameters. The present study is the first analysis of immunological effects induced by adjuvants in cancer patients who undergo chemotherapy, who are enrolled in the currently ongoing cancer vaccine clinical trials. The results show that the RNAdjuvantĀ® is a potent and Th1 driving adjuvant, compared to those tested in the present study. Most importantly, it is demonstrated that chemotherapy does not significantly impair the immune system, implying that cancer patients are likely to respond to a cancer vaccine even after a chemotherapy treatment.
      datePublished:2020-01-23T00:00:00Z
      dateModified:2020-01-23T00:00:00Z
      pageStart:1
      pageEnd:17
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12967-020-02218-x
      keywords:
         Adjuvant
         Colon cancer
         Lung cancer
         Immune-response
         Cancer vaccine
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig8_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig9_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig10_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig11_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12967-020-02218-x/MediaObjects/12967_2020_2218_Fig12_HTML.png
      isPartOf:
         name:Journal of Translational Medicine
         issn:
            1479-5876
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Angela Mauriello
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Carmen Manolio
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Beatrice Cavalluzzo
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Antonio Avallone
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:GI Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marco Borrelli
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alessandro Morabito
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Emanuele Iovine
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Angela Chambery
            affiliation:
                  name:UniversitĆ  della Campania ā€œLuigi Vanvitelliā€
                  address:
                     name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rosita Russo
            affiliation:
                  name:UniversitĆ  della Campania ā€œLuigi Vanvitelliā€
                  address:
                     name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maria Lina Tornesello
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Franco M. Buonaguro
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maria Tagliamonte
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Luigi Buonaguro
            url:http://orcid.org/0000-0002-6380-7114
            affiliation:
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
                  address:
                     name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Translational Medicine
      issn:
         1479-5876
      volumeNumber:18
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:GI Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:UniversitĆ  della Campania ā€œLuigi Vanvitelliā€
      address:
         name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
         type:PostalAddress
      name:UniversitĆ  della Campania ā€œLuigi Vanvitelliā€
      address:
         name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
      address:
         name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Angela Mauriello
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Carmen Manolio
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Beatrice Cavalluzzo
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Antonio Avallone
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:GI Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Marco Borrelli
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Alessandro Morabito
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Emanuele Iovine
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Angela Chambery
      affiliation:
            name:UniversitĆ  della Campania ā€œLuigi Vanvitelliā€
            address:
               name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
               type:PostalAddress
            type:Organization
      name:Rosita Russo
      affiliation:
            name:UniversitĆ  della Campania ā€œLuigi Vanvitelliā€
            address:
               name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
               type:PostalAddress
            type:Organization
      name:Maria Lina Tornesello
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Franco M. Buonaguro
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Maria Tagliamonte
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Luigi Buonaguro
      url:http://orcid.org/0000-0002-6380-7114
      affiliation:
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€
            address:
               name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:GI Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Thoracic Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
      name:Environmental, Biological and Pharmaceutical Science and Technology Dept, UniversitĆ  della Campania ā€œLuigi Vanvitelliā€, Caserta, Italy
      name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Laboratory of Molecular Biology and Viral Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy
      name:Laboratory of Cancer Immunoregulation, Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS ā€œFondazione Pascaleā€, Naples, Italy

External Links {šŸ”—}(202)

Analytics and Tracking {šŸ“Š}

  • Google Tag Manager

Libraries {šŸ“š}

  • Clipboard.js
  • Particles.js
  • Prism.js

CDN Services {šŸ“¦}

  • Crossref

5.09s.